Healthcare Business

fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
surgeons

Are Volcano Shareholders Getting Enough in the Buyout?

Volcano Corp. (NASDAQ: VOLC) announced that it has entered into a definitive agreement to be acquired by Koninklijke Philips N.V. (NYSE: PHG). The buyout is priced at $18 per share ...
Read Full Story »
Pfizer logo

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it ...
Read Full Story »
biotech

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
IPO

Bellicum Sets Pricing Terms for IPO

Bellicum Pharmaceuticals filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The price for the offering was set between $15 ...
Read Full Story »
biotech

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck & Co. Inc.'s (NYSE: MRK) big jump into the antibiotic space with the purchase of Cubist Pharmaceuticals Inc. (NASDAQ: CBST), sporting a 35% premium for shareholders, already has many ...
Read Full Story »
Pills

Merck, Cubist Agree to $9.5 Billion Acquisition

Drug giant Merck & Co. (NYSE: MRK) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST) have signed a definitive merger agreement under which Merck will acquire Cubist for $102 a share, or, ...
Read Full Story »
payoff

MannKind Sees More Insider Selling

MannKind Corp. (NASDAQ: MNKD) saw its shares trading lower on Thursday, on what was a day with little or no real news from the company. The culprit may simply be ...
Read Full Story »
DNA

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma Inc. (NASDAQ: ARRY) announced Wednesday after the market close that it had reached a definitive agreement with Novartis A.G. (NYSE: NVS) to regain full worldwide rights to cancer ...
Read Full Story »
thumbs up

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Credit Suisse has released a biotech research report from analysts Jason Kantor and Jeremiah Shepard that has their top picks for upside potential in the biotech segment for 2015. The ...
Read Full Story »
Pills

Are Avanir Shareholders Getting Enough in the Buyout?

Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) announced that it has entered into a definitive agreement with Japan’s Otsuka Pharmaceutical for a $17.00 per share buyout. Monday’s closing price was $15.00. After ...
Read Full Story »
fda_logo

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks. These events refer to reviews and decisions by the U.S. Food ...
Read Full Story »
biotech

Regenerative Medicine Company on Track for IPO This Week

The week after the Thanksgiving holiday stacks up to be another quiet one on the initial public offering (IPO) front. In fact, from now until mid-to-late January we are not ...
Read Full Story »
DNA

Mixed Readings For Biotech Short Interest

The short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
145922793

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Amgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue ...
Read Full Story »